Bioequivalence of Survodutide (BI 456906) When Administered Via Pre-filled Syringe (Formulation A) and Pre Filled Pen (Formulation B2) in Male and Female Trial Participants Who Are Healthy or Otherwise Healthy With Overweight/Obesity (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)

The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way.
Participants visit the study site regularly. During study visits, the doctors collect information about participants' health. To assess the study endpoints, participants regularly have blood samples taken.

Start Date03 Mar 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07206290

/ Not yet recruitingPhase 2

Albuminuria Reduction Trial and Investigation With Survodutide Treatment in CKD

The ARTIST-CKD trial is a clinical study evaluating the effect of weekly subcutaneous administration of survodutide (3.6 mg) on kidney function in patients with chronic kidney disease (CKD) and elevated albuminuria. The primary objective is to determine whether survodutide leads to early, sustained, and clinically meaningful reductions in albuminuria, regardless of diabetes status.

Start Date02 Mar 2026

Sponsor / Collaborator

Universitair Medisch Centrum Groningen

NCT07221591

/ Active, not recruitingPhase 1

Relative Bioavailability of Two Survodutide (BI 456906) Formulations When Administered Subcutaneously Via Pre-filled Syringe Over 28 Weeks (an Open-label, Randomised, Multiple Dose, Parallel Group Trial)

This study is open to healthy people between 18 and 65 years of age. People can join the study if they have a body mass index between 27 and 39.9 kg/m2.
The purpose of this study is to test a new formulation of a medicine called survodutide. Survodutide is being developed to help people with obesity and people with liver conditions. When a new formulation is developed, it is important to understand how it is taken up by the body.
Participants are divided into 2 groups by chance. One group gets the reference formulation of survodutide (formulation A). The other group gets the new formulation of survodutide (formulation B2). Participants in both groups inject survodutide under their skin once a week for about 6 and a half months.
Participants are in the study for about 7 months. During this time, they visit the study site 15 times. For one of the visits, participants stay overnight for 3 nights at the study site. The site staff takes blood samples to measure how much survodutide is in the blood. They also check participants' health and take note of any unwanted effects.

Start Date05 Nov 2025

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Survodutide

100 Translational Medicine associated with Survodutide

100 Patents (Medical) associated with Survodutide

Literatures (Medical) associated with Survodutide

01 Mar 2026·Molecular Metabolism

Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation

Article

Author: Klein, Holger ; Doerr, Jonas ; Augustin, Robert ; Jarosch, Sebastian ; Hecksher-Sørensen, Jacob ; Zimmermann, Tina ; Chehimi, Samar N ; Lam, Daniel ; Roostalu, Urmas ; Hayes, Matthew R ; Pekcec, Anton ; Crist, Richard C ; Perens, Johanna ; Bleymehl, Katherin ; Reiner, Benjamin C ; Haebel, Peter

Survodutide is a novel GCG/GLP-1 receptor (GCGR/GLP-1R) dual agonist in clinical development for people with obesity and people with metabolic dysfunction-associated steatohepatitis (MASH). Preclinically, survodutide demonstrated body weight lowering efficacy through decreased energy intake and increased energy expenditure. Here, we investigated the central site of action of survodutide and provide further insights into its mechanism of action in reducing body weight. We assessed GCGR and GLP1R expression in human and mouse circumventricular organs (CVOS) and showed for the first time that GCGR is barely detectable in area postrema (AP) and arcuate nucleus of the hypothalamus (ARH) at the single cell level. In contrast, GLP1R is expressed in these tissues. Using a fluorophore labeled survodutide to visualize sites of action in the mouse brain, survodutide was observed to directly access the CVOs and adjacent hypothalamic and hindbrain nuclei, without evidence of uniformly crossing the blood-brain-barrier. In addition, c-Fos labeling showed that multiple nuclei associated with the control of food intake were activated by survodutide. Consistent with the hypothesis that the intake suppressive effects of survodutide are GLP-1R dependent, a long-acting GCGR agonist did not induce neuronal activation in satiety-mediating regions, nor reduced food intake but showed reduction in body weight. These data further support the dual mode of action of survodutide and its potential to provide clinical benefit for people with obesity and/or MASH.

01 Mar 2026·Endocrinology, diabetes & metabolism

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials

Review

Author: Raged Gharbia ; Ayah Abulehia ; Barbara Gisella Carranza Leon ; Doha Jaber ; Omar Ayesh ; Hamzeh Abugharbieh ; Lila H. Abu-Hilal ; Adham Itbaisha ; Thekrayat Asad ; Hazem Ayesh

ABSTRACT:

Introduction:

Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight‐reducing effects. Several investigational GRA‐based agents, including retatrutide, cotadutide, mazdutide, and survodutide, have reported promising results across early and mid‐phase clinical trials. This comprehensive meta‐analysis evaluates the efficacy and safety of these agents in individuals with type 2 diabetes, overweight, or obesity.

Methods:

PubMed, Cochrane, Embase, and Scopus databases were systematically searched. Fourteen randomised controlled trials meeting the inclusion criteria were analysed using frequentist network meta‐analysis. Random‐effects models were applied to assess mean differences (MD) in weight change, both absolute and percent changes, HbA1c, adverse events, and discontinuation due to adverse events. Heterogeneity was quantified using the I2 statistic.

Results:

Retatrutide demonstrated the greatest weight reduction versus placebo (MD −13.44 kg; 95% CI [−18.38, −8.51]), followed by survodutide (MD −10.74 kg; 95% CI [−15.68, −5.80]) and mazdutide (MD −6.47 kg; 95% CI [−10.71, −2.24]). Cotadutide showed the smallest and nonsignificant effect (MD −3.41 kg; 95% CI [−11.63, 4.81]). Regarding HbA1c reduction, retatrutide showed the largest effect, followed by survodutide, mazdutide, and cotadutide; however, only the effect of retatrutide reached statistical significance. In terms of safety, mazdutide demonstrated the most favourable tolerability profile, whereas retatrutide and cotadutide were associated with comparatively lower tolerability.

Conclusions:

Retatrutide and survodutide exhibit the most favourable efficacy profiles for obesity and T2DM, with acceptable safety. These findings support their potential clinical use and highlight the need for future head‐to‐head trials.

01 Feb 2026·Contemporary Clinical Trials Communications

Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation

Article

Author: Recaldin, Christopher ; Daniëls, Wouter ; Mooney, Vicki ; Baanstra, David ; van de Walle, Viviënne ; Rubino, Domenica M ; Nadglowski, Joe

Introduction:

Clinical trial simulations (CTSs) are an increasingly common way to incorporate site staff and participant feedback into clinical trial design. CTSs can help overcome the unique challenges presented in obesity trials. Here, a CTS was conducted for three trials from the SYNCHRONIZE™ phase 3 program of survodutide in obesity.

Methods:

Individuals meeting the inclusion criteria of the SYNCHRONIZE trials (referred to as "participants"), and clinical trial professionals with experience in conducting obesity trials ("site staff"), were recruited. Trial designs were reviewed by participants and site staff, and participant-facing materials by participants. Both groups were interviewed about these aspects of the trials.

Results:

Overall responses to the clinical trial designs were positive. Site staff were comfortable with the inclusion/exclusion criteria and thought recruitment would not be difficult. However, they indicated that pre-screening could help ensure participants' appropriateness for the trial. Additionally, they felt steps should be taken to encourage participant engagement throughout the trial. Participants' concerns focused on optimizing training and educational materials, time commitments for the trial, and burden of data collection. Recommendations from the CTS led to changes in visit interval, increased virtual visit options, and changes in participant materials. Psychological support was identified as potentially helpful by both site staff and participants. However, understanding how to implement this in clinical trials remains to be elucidated.

Conclusions:

These results suggest participant and site staff input from a CTS could help improve obesity clinical trial design, which may ultimately lead to more robust data and reliable clinical findings.

140

News (Medical) associated with Survodutide

25 Mar 2026

·endpoints.news

Boehringer Ingelheim plans for dealmaking, obesity pipeline and R&D to counter US price pressure

Boehringer Ingelheim said it plans to keep up high levels of R&D spending, and could look at China-based companies for dealmaking, as key planks of its strategic approach this year, board chairman Shashank Deshpande said Wednesday. Deshpande was discussing the company’s 2025 performance on a call with members of the media. Last year, the German biopharma’s human drug sales grew 7.4% on a constant currency basis to €22.7 billion ($26.3 billion), and the company expects a similar trend this year. “We expect to grow this year on a comparable basis, adjusted for currency and extraordinary effects,” said Deshpande, who also heads Boehringer’s human pharma business unit. The company’s biggest money-makers in 2025 were once again its diabetes and heart drug Jardiance and the lung disease med Ofev. But sales in the US shrank 2% from 2024, hit by “quite substantial reductions in price” in the country. The Medicare prices of Jardiance, Ofev and the diabetes therapy Trajenta are all now negotiated under the IRA. If the impact on pricing in the US were to be excluded, finance chief Frank Hübler said, “we would have also grown there as we did in Europe and other regions.” The advent of new products could help. Boehringer has won two approvals so far this year, with the lung cancer treatment Hernexeos and the idiopathic pulmonary fibrosis drug Jascayd . It also has an obesity drug that’s drawing attention. Survodutide, which Boehringer licensed from Zealand Pharma, is in two pivotal trials, and data are due at the American Diabetes Association meeting in June. “I would expect to see good weight loss in the context of important effects on the general metabolic [health] and particularly the liver,” Boehringer’s head of innovation Paola Casarosa told Endpoints News in an interview. Pressed on what good weight loss might look like, she declined to name a target percentage, but suggested that Boehringer is focused on quality over quantity: It wants to see if patients retain more muscle than on other incretin drugs, Casarosa said. Side effect rates have also been a key differentiator for the class. The drug is unlikely to reach market before the second half of 2027 — and even that might be ambitious. How will Boehringer compete with Eli Lilly and Novo Nordisk, and possibly also new entrants such as Pfizer and Roche? “It would be sort of arrogant to expect, well, we’re going to have a molecule that’s completely different from anything else,” Casarosa said. But survodutide has the unusual mechanism of GLP-1 and glucagon agonism — making it a potentially unique approach in a world of drugs that either only target GLP-1, or go after a different set of targets. Casarosa said she hopes that its glucagon agonism could allow survodutide to be particularly useful for obesity patients who also have liver disease. Phase 3 trials in the fatty liver condition known as MASH are also due this year. Boehringer also revealed on Wednesday that another obesity asset, its triple agonist, will head into Phase 2 this year. The program is somewhat mysterious: Casarosa declined to confirm its exact mechanism, so it might not be what’s known as a triple-G — an agonist of GLP-1, GIP and glucagon — like Lilly’s retatrutide or Novo Nordisk’s UBT251 . “We are investing with full speed and energy to the next steps, because we see the potential to really have strong weight loss in the context of, in our hands, unprecedented tolerance,” Casarosa said of the drug, which is called BI 3034701. Boehringer is developing it in collaboration with the Danish biotech Gubra. Survodutide and the triple agonist entered Boehringer’s pipeline via partnering deals, and they won’t be the last assets to follow this path. The company is looking at collaboration opportunities in China, and intends to stay in its familiar therapeutic areas of cardiovascular-renal-metabolism, oncology, inflammation and respiratory, and mental and eye health. “We would be looking at innovation and how we can leverage the upcoming innovation in China, how we can leverage Chinese speed in development — but all through the lens of our existing research portfolio,” Deshpande said on the media call. Alongside external sources of new products, the company is committed to spending on in-house R&D. It now plows over 27% of its net pharmaceutical sales into R&D for human therapeutics. About 40 to 50% of Boehringer’s portfolio has some elements of external innovation, Casarosa said, whether acquisitions, licensing or use of external technologies to make the molecules. She also pointed out that through its corporate venture fund, Boehringer can help seed new technologies.

Phase 2Phase 3

18 Mar 2026

·www.prnewswire.com

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the Institutional Review Board (IRB) at Clinical Pharmacology of Miami has approved the Company's Phase 1 Part 3 clinical trial of its lead asset, DA-1726, a novel, dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. The approval enables initiation of Part 3 of the Phase 1 program, which consists of two 16-week titration cohorts evaluating one-step and two-step dose-escalation strategies intended to safely reach higher target doses and further optimize tolerability. The Phase 1 Part 3 trial will enroll a total of 40 obese, otherwise healthy adult subjects, across two parts, with 20 subjects per part, randomized 4:1 (16 active; 4 placebo). Part 3A is designed to evaluate a one-step titration regimen with 16 mg for 4 weeks followed by 48 mg for 12 weeks, while Part 3B will evaluate a two-step titration regimen with 16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks. The study will assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs leading to treatment discontinuation. Secondary and exploratory endpoints include PK profiling and evaluation of metabolic, glycemic, lipid, and body composition measures, including weight, waist circumference, and body mass index (BMI), and other cardiometabolic measures. "This IRB approval marks a key milestone in the advancement of DA-1726 and builds on the program's increasingly compelling clinical profile across efficacy, safety, and tolerability," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "In earlier cohorts, the 48 mg dose produced approximately 9% weight loss, meaningful reductions in waist circumference, improved blood sugar control, and early signals of direct liver benefit, all with a favorable safety profile. Our upcoming 16-week titration studies to 48 mg and 64 mg doses are designed to build on these results and further highlight DA-1726's favorable tolerability and potential advantage relative to currently marketed therapies that require slower, more extended titration before achieving full therapeutic dosing. With initial dosing expected to begin in April and data expected in the fourth quarter of 2026, we believe these results will further de-risk the program and support advancement of DA-1726 into later-stage development, reinforcing its potential as a differentiated, next-generation GLP-1-based therapy that could offer meaningful advantages over existing options." About DA-1726 DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in pre-clinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy®), a leading GLP-1 receptor agonist. Additionally, in pre-clinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction. About MetaVia MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects. For more information, please visit . Forward Looking Statements Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia's ability to execute on its commercial strategy; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts: MetaVia Marshall H. Woodworth Chief Financial Officer +1-857-299-1033 [email protected] Rx Communications Group Michael Miller +1-917-633-6086 [email protected] SOURCE MetaVia Inc. 21% more press release views with Request a Demo

Phase 1Clinical ResultPhase 2

23 Feb 2026

·www.fiercepharma.com

Obesity Power Rankings: Who will challenge Lilly and Novo?

None With the obesity market projected to exceed $130 billion by 2034, many major pharmaceutical players are rapidly advancing pipelines to capitalize on what is arguably the most dynamic space in the industry. To identify the companies positioned to outperform, FENIX has created the Obesity Power Rankings of the Top 10 players. For context, >20 companies were assessed across more than 15 weighted criteria, including pipeline depth, clinical differentiation, and commercial infrastructure, to derive a composite score out of five. If you’re interested in a deeper look at the full assessment framework, please contact the FENIX team. Below, FENIX outlines the rationale for all rankings and highlights key headwinds and tailwinds that shape each company’s position: Lilly (4.9/5): Lilly remains the undisputed market leader in obesity, as evidenced by its tirzepatide franchise becoming the world’s top-selling drug in 2025, surpassing Merck’s Keytruda to generate >$36 billion in annual revenue. While Lilly possesses a robust late-stage pipeline which is anticipated to help defend its leadership position, near-term momentum is expected to center on the orforglipron launch in Q2 2026. Considering Novo’s Wegovy Pill appears to hold a marginal edge in terms of efficacy, Lilly’s commercial team may need, for once, to come from behind. Novo Nordisk (4.8/5): Having effectively pioneered the modern obesity market with semaglutide, Novo entered 2026 confronting a convergence of executional challenges and a visible decline in innovation, factors that culminated in the company issuing its first negative annual sales outlook since semaglutide’s ascent. Novo now relies on strong launches of injectable 7.2mg Wegovy, Wegovy Pill, and CagriSema to stabilize its US market share and rebuild investor confidence. While these launches may alleviate near-term pressures, it remains uncertain whether Novo has truly identified a long-term successor to semaglutide. Pfizer (4.1/5): Following its $10 billion Metsera acquisition and licensing agreement with YaoPharma in 2025, Pfizer has significantly vaulted up the competitive rankings. While the company previously faced multiple setbacks in obesity (e.g., danuglipron and lotiglipron discontinuations), Pfizer finally appears to have assembled a differentiated pipeline that can fully leverage its established commercial and manufacturing infrastructure. Roche (4.0/5): Despite its historically limited presence in the cardiometabolic space, Roche has publicly emphasized its ambition to become a Top 3 player in the obesity market. Following the recent encouraging topline CT‑388 Phase 2 results, attention now turns to the upcoming Phase 2 petrelintide readout in H1 2026, a pivotal catalyst that will likely shape the trajectory of its partnership with Zealand and, ultimately, Roche’s broader obesity aspirations. AstraZeneca (3.6/5): A compelling case can be made that AZ has the pipeline depth to emerge as a dark horse contender for the third-place position in the power rankings. The company quietly advanced a broad mid-stage pipeline throughout 2025; and with multiple Phase 2 readouts expected in 2026, it's licensing agreement with CSPC Pharmaceuticals, which added a monthly dual agonist to its arsenal, further strengthens it as a serious contender. Amgen (3.3/5): Amgen is effectively placing a concentrated bet that MariTide’s extended dosing will be its key differentiator in the future obesity market. While quarterly maintenance dosing is differentiated, it remains to be seen whether the company can overcome the Phase 2 tolerability issues that unsettled investors at ADA 2025. Boehringer Ingelheim (3.0/5): With data from the Phase 3 survodutide program anticipated to begin reading out in H1 2026, BI is set to become the first challenger to the current Lilly+Novo duopoly. Even with positive Phase 3 survodutide data, BI likely needs to expand its pipeline beyond its Phase 2 triple agonist to become a long-term competitive player in the space. Regeneron (2.9/5): While it was previously believed Regeneron was taking a tangential approach in the obesity market, looking to develop lean mass-sparing assets, its in-licensing deal for olatorepatide in June 2025 revealed the company’s broader obesity ambitions. However, similar to both BI and Amgen, it is believed Regeneron also needs to further diversify its portfolio to be considered a future leader in obesity. Zealand Pharma (2.4/5): Zealand, guided by CEO Adam Steenburg’s ambition to end what he describes as the “Weight Loss Olympics,” is making a strategic bet that amylin will become the next foundational anti-obesity class. Following Zealand’s partnership with Roche for petrelintide, the upcoming Phase 2 ZUPREME-1 readout will offer the first meaningful look into whether petrelintide lives up to the TPP promise. Kailera Therapeutics (2.2/5): Having licensed China-based Hengrui’s GLP-1/GIP dual agonist (ribupatide), which has already demonstrated strong late-stage weight loss efficacy in a Chinese population, Kailera initiated its own Phase 3 program evaluating higher doses (>6 mg) over longer treatment durations. It will be interesting to see if Kailera follows the traditional path of partnering with Big Pharma or if it goes alone with a new US commercial model (i.e., solely direct-to-patient).

Phase 3Phase 2License out/in

100 Deals associated with Survodutide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Cirrhosis	Phase 3	Argentina	Boehringer Ingelheim (China) Investment Co., Ltd.	14 Oct 2024
Cicatrix	Phase 3	-	Boehringer Ingelheim GmbH	08 Oct 2024
Fibrosis, Liver	Phase 3	United States	Boehringer Ingelheim GmbH	17 Sep 2024
Fibrosis, Liver	Phase 3	China	Boehringer Ingelheim GmbH	17 Sep 2024
Fibrosis, Liver	Phase 3	Japan	Boehringer Ingelheim GmbH	17 Sep 2024
Fibrosis, Liver	Phase 3	Argentina	Boehringer Ingelheim GmbH	17 Sep 2024
Fibrosis, Liver	Phase 3	Australia	Boehringer Ingelheim GmbH	17 Sep 2024
Fibrosis, Liver	Phase 3	Austria	Boehringer Ingelheim GmbH	17 Sep 2024
Fibrosis, Liver	Phase 3	Belgium	Boehringer Ingelheim GmbH	17 Sep 2024
Fibrosis, Liver	Phase 3	Brazil	Boehringer Ingelheim GmbH	17 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04771273 (1404-0043, CTgov)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	295	Survodutide (Survodutide 2.4 mg - Planned Maintenance Treatment)	yjysbrsenb = gxuwjaidou kthxtdvyjl (humuxnvwfx, mftmhawdkk - gxdnokcwdr) View more	-	03 Dec 2024
				Survodutide (Survodutide 4.8 mg - Planned Maintenance Treatment)	yjysbrsenb = dirgebpkpa kthxtdvyjl (humuxnvwfx, qlfqtvwglf - yaiuqjgcca) View more
ESC2024	Phase 2	Obesity	387	Survodutide 4.8 mg	capuouktze(ratdpkbflj) = kfjqcriqmm fbfmsnwljf (pvnctqsdsa )	Positive	01 Sep 2024
NCT04153929 \| NCT04667377 \| NCT03591718 (1665-P, ADA2024)	Phase 1/2	Diabetes Mellitus, Type 2 \| Obesity HbA1c \| insulin sensitivity \| glucose biomarkers ... View more	-	Survodutide	pgyqlzketl(fzwternjxp) = 0.4 vs 0.0 lrqbzdnwlt (ozhijmcynk ) View more	Positive	14 Jun 2024
				Placebo
NCT04771273 (1404-0043, Pubmed)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	293	Survodutide 2.4 mg	qmmwxyyeeu(zrwpvgufnj) = muovipauun abnewukess (ggadlsgkft ) View more	Positive	07 Jun 2024
				Survodutide 4.8 mg	qmmwxyyeeu(zrwpvgufnj) = yfzskuyoag abnewukess (ggadlsgkft ) View more
NCT04667377 (Phase II Trial, ENDO2024)	Phase 2	Overweight \| Obesity	384	Survodutide 4.8 mg	atrcxlejrn(nrobgzskmh) = sllfggnkzp xijaiiugoe (lnaajzmpqi )	Positive	01 Jun 2024
				Placebo	atrcxlejrn(nrobgzskmh) = ginkzkufro xijaiiugoe (lnaajzmpqi )
NCT04771273 (GlobeNewswire) Manual	Phase 3	Metabolic Dysfunction Associated Steatohepatitis	-	survodutide	hmlyrsakty(rcgxrgggqj) = hmsttlrbkh ogtzikeojo (leznrpmccp ) Met	Positive	26 Feb 2024
				Placebo	hmlyrsakty(rcgxrgggqj) = mlpqmxhncz ogtzikeojo (leznrpmccp ) Met
NCT04771273 (Corporate Publications) Manual	Phase 2	Metabolic dysfunction-associated steatotic liver disease	295	Survodutide	xvhrkqqbld(gyagmrkfzu) = rfystmfquk dfzranvcew (uwndqaneww ) Met	Positive	26 Feb 2024
				placebo	xvhrkqqbld(gyagmrkfzu) = daqlrnmvbr dfzranvcew (uwndqaneww ) Met
NCT04667377 (Phase II Trial, CTgov)	Phase 2	Obesity	387	BI 456906 (0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation))	xezdyqlrab(yzsbfrtkjy) = zbcncxwtzq xkfvoboyzt (skhybaffdx, 1.07) View more	-	02 Nov 2023
				BI 456906 (2.4 mg BI 456906 - Planned Maintenance Treatment)	xezdyqlrab(yzsbfrtkjy) = tcrhsygblz xkfvoboyzt (skhybaffdx, 1.01) View more
NCT04667377 (ADA2023) Manual	Phase 2	Overweight \| Obesity	387	BI 456906 0.6 mg	jnhdgbnqbi(jeiuzxsfkg) = akgydspggp iwofwqekib (rtdubcqzqw ) View more	Positive	23 Jun 2023
				BI 456906 2.4 mg	jnhdgbnqbi(jeiuzxsfkg) = fthzekcavm iwofwqekib (rtdubcqzqw ) View more
NCT04153929 (Phase II, CTgov)	Phase 2	Diabetes Mellitus, Type 2	413	Placebo (Placebo)	eahxlbedzs(byhzrsajlw) = ciyqqfwunn xfqbetnmvc (qlkbafhpxr, 0.81) View more	-	29 Nov 2022
				BI 456906 (BI 456906 0.3 mg)	eahxlbedzs(byhzrsajlw) = rvwmqdbwit xfqbetnmvc (qlkbafhpxr, 0.71) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis